Jean-Jacques Garaud, MD Global Head Pharma ... - Roche

More documents

Recommendations

Info

New R&D model Innovation truly at its core Translational Medicine Customized /original design System Biology Understanding complexity Innovation Modeling and Simulation Driving decision-making process Biomarkers Relevant tools 4
Biomarkers A central element throughout the life cycle of a medicine • Biomarkers are critical for translational medicine, exploratory and confirmatory development strategies - Improved decision making in R&D (e.g. tools for profiling targets, compounds, PD Markers) - Understanding pathways and mechanisms (e.g. pt. subpopulations, optimized patient stratification) - Drivers for pharmacodiagnostic development e.g. increased benefit/risk ratio, companion diagnostics) • Biomarkers are a central element throughout the lifecycle of a medicine from target ID to market 5
Page 1 and 2: Clinical Development at Roche: Driv
Page 3: Our new R&D model: Paradigm changes
Page 7 and 8: Our new R&D model: Paradigm changes
Page 9 and 10: Enhance innovation …by maintainin
Page 11 and 12: Roche Pharma pipeline overview Focu
Page 13 and 14: Major Roche-managed oncology submis
Page 15 and 16: Avastin and cetuximab in combinatio
Page 17 and 18: Avastin and cetuximab in combinatio
Page 19 and 20: Attacking the HER2 pathway from mul
Page 21 and 22: Implementing biomarker strategy for
Page 23 and 24: Key drivers for long term developme
Page 25 and 26: Actemra: The first IL-6 receptor in
Page 27 and 28: CETP Inhibitor R1658 is a unique CE
Page 29 and 30: Taspoglutide: investigational once-
Page 31 and 32: CD20 targeting: new treatment strat
Page 33 and 34: Roche R&D opportunities in summary
Page 35 and 36: Avastin’s position as standard of

Jean-Jacques Garaud, MD Global Head Pharma ... - Roche

Create successful ePaper yourself

Delete template?

Save as template?